Arcus Biosciences to Report First Quarter 2022 Financial Results and Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc.(NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced it will report financial results and key pipeline updates for the first quarter ended March 31, 2022 after the U.S. markets close on Monday, May 9, 2022.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor) and most recently, HIF-2a. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit or follow us on Twitter.


Media Inquiries
Holli Kolkey
VP of Corporate Communications
(650) 922-1269

Investor Inquiries
Pia Banerjee
Head of Investor Relations & Strategy
(617) 459-2006


Source: Arcus Biosciences

Back to news